Real-time · AI · Cross-signal

Vilya just raised. Here's exactly what to do next.

Who to reach, what to say, and why now — on Vilya, plus every funding round, exec hire, and M&A move that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your plan Request a demo

Everyone else gives you a piece

✕Crunchbase & PitchBook list the company — No person, no timing, no opener.

✕ZoomInfo & Apollo sell you a contact — No trigger, no reason to reach out now.

✕LinkedIn Sales Navigator shows you people — No real-time signal, no opener.

✕Clay enriches lists you built — No live signal of its own, no who or when.

✕ChatGPT & gen-AI tools answer on a delay — No live data, no verified contact.

Who to contactWhat to sayWhen to reach outWhy now

Only Fundz delivers all four.

Vilya Expands Series A Financing to $71 Million led by ARCH Venture Partners for Computational Drug Design

PRIVATEJun 04, 2024•almost 2 years ago

Amount Raised

$71 Million

Round Type

series a

Investors

Altitude Life Science VenturesLifeforce CapitalMadronaMenlo VenturesNvidia’s N VenturesArch Venture Partners

Description

VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, announced today an expanded $71 million Series A financing. The funding will accelerate the advancement of Vilya's proprietary computational drug design and development platform and its pipeline of novel macrocycles that precisely target disease biology.

Vilya just raised. Here's exactly what to do next.

Vilya Expands Series A Financing to $71 Million led by ARCH Venture Partners for Computational Drug Design

Investors

Description

Company Information

Funding Insights